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Summary  
The care of people with first episode mania has been overlooked in comparison to 
people with other non-affective psychoses, despite evidence suggesting targeted 
treatments may be of benefit for this patient group. In this personal view, we outline 
the epidemiology of first episode mania in the context of bipolar disorder in general, 
the natural history of mania (with emphasis on its recurrent nature), current evidence 
for pharmacological, psychological, service-level interventions and current guidelines 
for first episode mania. We note the paucity of high quality evidence for interventions 
in first episode mania, and the lack of agreement amongst treatment guidelines in 
relation to treatment-especially maintenance treatment. We suggest that, based on 
high morbidity and clinical need, research evidence to guide guideline development 
is necessary, and in the interim, clearer guidance should be given, specifically 
suggesting they should be looked after within first episode psychosis service, where 
they exist. 
Word count;147 words 
Research in Context 
Evidence before this study 
Care for people with first episode mania is not uniform across similar health systems. 
Very few trials have examined interventions in this patient group, despite evidence 
which suggests targeted interventions may be of benefit.  
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We highlight the need for clearer treatment guidance for people with first episode of 
mania, and need for targeted care for this patient group, identifying gaps in level 1 
evidence.  
Implications of all the available evidence 
Further effort should be made to ensure optimised care of this patient group within 
existing services and further research is required to establish longer-term 
effectiveness of specific pharmacological, psychological and service-level 
interventions.  
Search strategy and selection criteria 
We searched PubMed for studies published in English from inception until 31st 
October 2018, using the MeSH headings ((early intervention OR first episode mania) 
AND bipolar disorder). This yielded 1174 results. Relevant guidelines from the last 
ten years were identified through manual search and examination by SJ and AR. 
Added value of this study 
This study highlights the factors that contribute to the health burden of first episode 
mania and makes suggestions for clearer treatment guidelines and further research 











There is increased awareness that psychiatric disorders may begin, evolve and are 
modifiable in youth. It should be noted that this increased awareness has only occurred in 
some centres and parts of the world (see below). 
The modifiable nature of intervention is based on research over the last thirty years, 
examining early detection and early intervention for psychosis/first episode 
psychosis (FEP) services (1). Motivation for FEP services came from longitudinal 
studies showing improved outcomes in people with first episode schizophrenia when 
treatment was initiated earlier (2), either with antipsychotics (3–5), and then 
psychosocial interventions (6), one hypothesis being that early, and for some, 
sustained treatment would improve long-term outcome.  
Although around 70% of those seen by these services fulfil diagnostic criteria for 
schizophrenia on follow-up, the criteria for entry were deliberately wide and people 
with affective psychosis are also included (13% bipolar disorder, 12% depression 
with psychosis in one cohort study)(7). This subgroup is mainly comprised of people 
with bipolar disorder (predominantly bipolar 1, who have experienced first-onset 
mania), which has strong diagnostic stability (8).   More importantly, the clinical 
picture, and response to treatment(s) in these patients can be quite different to that 
in those with schizophreniform psychosis (please see Table 1).  
However, specific advice for this population is often missing from most, but not all, 
National guidelines, some of the current recommendations being inconsistent with 
evidence and/or clinical practice. The objective here is to review epidemiology, 
clinical presentation, natural history and treatment interventions for first episode 
bipolar disorder, specifically first episode mania– the point of definitive diagnosis. We 
highlight need for targeted care for this population within existing FEP services, 
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earlier recognition, and targeted care within Child and Adolescent Mental Health 
Services (CAMHS) and generically.  
Epidemiology and health burden 
Prevalence estimates for bipolar disorder (BD) vary, depending on  criteria and 
country, the WHO World Mental Health Survey estimating 0.6% for Bipolar 1, 0.4% 
for Bipolar II, and 2.4% for bipolar spectrum disorder (9). It is worth noting that the 
terminology for bipolar disorder has changed in ICD 11 and DSM-5, significant points 
being incorporation of bipolar II in ICD 11 and the additional requirement of 
increased activity (to mood elation or irritability) in both classification systems (10). 
Incidence rates of BD also vary, from 2.2/ 100 000 person years (PYs) in rural 
Ireland to 12.3/100 000 PYs in Finland, probably due to methodological factors 
(diagnostic threshold, availability of inpatient beds, and sampling methods) (11).  
Given that a significant number of people with first episode mania will develop 
psychosis, it is also worth examining the psychosis literature. A systematic review of 
UK studies in psychoses identified incidence of bipolar psychosis of 3.7/100 000 
PYs, with significant heterogeneity (12). An older registry-based sample from 
Camberwell, London, from 1965 to 1999, identified incidence of first episode mania 
of 16.8/100,000 PYs in those aged 21 to 25 years (using 5-year age bands). This 
declined thereafter, with a small peak in later life (40-55 years) (13) (see below for 
discussion of age of onset, and Table 2). This is consistent with late adolescent 
modal onset.   
Morbidity and mortality are both increased in BD, recent UK data indicating 
increased mortality compared to the general population, at least 12 times increased 
suicide risk (more than schizophrenia) and 50 times the risk of self-harm (14). Data 
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from the WHO Global Burden of Disease study ranked BD as the 4th leading cause 
of disability adjusted life years in people aged 10-24 (15).  
There is a dearth of representative studies examining first episode manic psychosis, 
especially within first episode psychosis (FEP) services.  Recent three year follow-up 
of a Hong Kong sample showed 37% of people with first episode manic psychosis 
(FEMP) attained functional remission, FEMP patients being more likely to be 
hospitalised than people with first episode schizophrenia (16).   
This contrasts with studies in other countries, one study finding no significant 
difference in days spent in hospital at 10-year follow-up between similar cohorts, with 
better GAF scores in those with bipolar disorder (17). 
Age of onset 
Determining age of onset is problematic, as first onset of mild depression, major 
depression, hypomania and mania may all occur at different time points; illness may 
have onset before elevated poles that define BD. Age of onset occurs at different 
time points, with three groupings proposed; late adolescence, mid-twenties and in 
middle life (18). In a review of eight admixture analyses studies (identifying normally 
distributed cases across age groups), three sub-groups were identified (early, 
intermediate and late) in all but one analysis (19). In their pooled analysis, 45% had 
onset before 21.33 years and 81% experienced first episode before 34.67 years.  
Using retrospective design, Berk et al identified median age of onset of mania of 
24.1 years, with median age of diagnosis of BD or schizoaffective disorder and 
initiation of diagnosis-appropriate treatment at 30 years (20).  Participants had their 
first depressive episode aged 21.2, with onset of any symptoms nearly 4 years prior 
to that. While retrospective data from adult and persistently unwell participants 
indicate later age of onset of mania, prospectively studied familial high-risk youths 
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suggest earlier age of first (hypo) mania (21). A recent meta-analysis of 27 studies 
suggested the interval between onset of BD and management was 5.8 years, high 
heterogeneity illustrating differences in definition of onset and management (22). 
Delay between onset of symptoms (of both depression and mania) and initial 
diagnosis underlines need for early identification and intervention(s). For first 
presentation of bipolar depression, this would focus on identifying clinical variables 
such as family history of BD, reverse vegetative symptoms (“atypical” symptoms, 
e.g., hypersomnia, hyperphagia, leaden paralysis), psychotic features (23), and 
treatment factors such as poor response to antidepressants and manic switching 
(24). For first presentation of mania, persistent symptoms, impairment and relapses 
are common (see below).  
Clinically, the perception that phenomenology of hypomania/mania differs depending 
on age of onset is borne out by evidence. A review of 9 studies suggested more 
irritability in childhood onset, increased activity more prevalent in adolescent onset, 
and increased pressure of speech in adult-onset illness. The authors identified lack 
of direct comparison between childhood and adult onset illness and heterogeneity 
amongst studies (25). Early age of onset (defined by the cut-off given by Geoffroy et 
al, above (18), is associated with increased suicide attempts, rapid cycling, drug 
abuse, obsessive–compulsive disorder and increased familial risk for affective 
disorders. Though focused discussion on cognitive function is outside the scope of 
this article, we note results of a recent longitudinal study of youths with bipolar 
disorder, followed over 2.5 years. This found no difference in measures of the 
Cambridge Neuropsychological Test Automated Battery (CANTAB) compared to 
CANTAB normative data, identifying three subtypes, the subtype with poorest 
function having more mood episodes (26). Several other studies and meta-analyses 
 8 
have pooled data together, demonstrating cognitive impairments even during 
euthymia, after recovery from first manic episode versus controls (in cognitive 
flexibility, though not response inhibition and verbal fluency), as well as established 
illness (27,28).  
Natural history; is bipolar disorder a recurrent illness? 
Modern theories of the natural and recurrent course of BD date back to 1851 and 
Falret’s concept of “folie circulaire”(28), where he described melancholic and manic 
episodes, interspersed with symptom free periods and generally poor outcome, 
though Kraepelin is generally credited with the distinction between affective 
psychoses and schizophrenia. To ascertain possible benefits of prophylactic 
treatment and natural course of illness requires examination of historical cohorts who 
did not receive prophylactic medication. We then examine studies conducted in the 
modern era, highlighting methodological considerations. 
In their careful review of 11 studies of over 6500 people with BD (using the 
Kraepelinian construct of both unipolar and bipolar illness) not taking prophylactic 
medication, Goodwin and Jamison concluded that recurrence is the rule, as opposed 
to the exception (29). Rates of single episode varied from 0-55%, older studies 
indicating higher rates, with significant numbers of single “episodes” being chronic 
and unremitting. They noted rates of recurrence had apparently increased in the 35 
years prior to their 2007 textbook (speculating antidepressants may have contributed 
to this). Interpretation of older studies is difficult, on account of factors such as 
Slater’s paradox, where analyses of Kraepelin’s cohort included total number of 
recurrent cases, as opposed to individual cases. This may have led to erroneous 
assertions, such as the rate of cycling increasing over time and periods of 
euthymia decreasing with more recurrences (30). In the Zurich longitudinal study, 
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219 patients with bipolar disorder, with median age at follow-up/death of 68 years, 
only 16% were considered to have sustained recovery (functional outcome 
measured by score on the Goal Attainment Scale (GAS) >60 and no episodes in the 
prior 5 years), approximately a quarter in remission (with an episode in the last 5 
years), and 27% with incomplete remission. Furthermore, rates of recurrence after 
first episode of illness appeared consistent over time (forty-year follow-up from first 
episode) (31). A strength of this study is the catchment area design, with follow-up of 
individual cases over time, as opposed to only those requiring hospitalisation (a possible 
bias of older studies.) 
Data on outcome after first episode mania in recent cohorts are limited by length of 
follow-up (longest follow-up 4 years), and it should be acknowledged that remission 
of episode does not necessarily reflect symptomatic or functional remission. For 
example, following remission of an initial manic syndrome, although 90% of subjects 
had syndromal recovery at 1 year, 40% were still experiencing anxiety and 
depression and nearly 60% failed to return to prior functioning (32). Regarding first 
episode mania studies, a recent systematic review of 8 studies estimated recurrence 
at 1 year at 41% and 59.7% at 4 years (33). A similar conclusion was reached by 
another systematic review, which included adolescents with first manic/mixed 
episode. This pooled data from 5 studies in adults, 3 studies giving recurrence rate 
of 35% at one year. Three studies in child and adolescent populations gave one year 
recurrence of 48%, 2 year recurrence of 46% and 4-5 year recurrence of 65% (34). If 
one considers that episodes accumulate over time (as in the Zurich longitudinal 
study), findings are in accordance with high recurrence risk over the lifetime. 
Recurrence rates also appear higher in established BD. An indirect measure of 
recurrence comes from the SPaRCLE trial, where 1172 people with bipolar I illness 
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(experiencing mania, depression or mixed episode) had illnesses stabilised with 
quetiapine and subsequently randomised to quetiapine, lithium or placebo. 
Quetiapine and lithium both increased time to recurrence of depression and manic 
symptoms over placebo at two-year follow-up (quetiapine HR 0.29, lithium HR=0.46), 
with recurrence in placebo group of approximately 48-56%, depending on index 
episode (mania, depression, mixed) (35). 
An influential model (the “kindling” hypothesis) postulates that life stress triggers the 
initial episode of illness, though these episodes eventually occur autonomously (36). 
This model incorporates animal work, relating to seizure stimulation, with less 
electrical stimulation required to elicit seizures in mice, with less electricity required 
to provoke seizure with each progressive seizure, with eventual spontaneous seizure 
activity (ie without stimulus). Behavioural sensitisation refers to the process whereby 
mice respond to psychomotor stimulants such as cocaine, both in the short and 
longer-term, with increased intensity of behavioural response over time. This has 
been used to explain the natural history of relapses in bipolar disorder, such as 
increased recurrence of episodes, independent of life-stress. Extrapolating this to 
clinical studies is difficult, on account of methodological issues, including 
quantification of life stress (both negative and positive), measurement of recurrence 
(as noted above) and inclusion of help-seeking populations. This was emphasised in 
a recent review which concluded that 8 of 15 studies in BD showed kindling effect, 
and methodological issues limited interpretation (37).  
Staging bipolar disorder and linking this to treatment 
Staging mental illness is a method of linking knowledge about the natural history of 
mental illness to putative treatments. This is in keeping with concepts in general 
medicine (e.g., oncology)(38). A staging model has been proposed for BD, 
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incorporating phases from those at increased risk of developing BD, through to initial 
presentation, recurrence and possible progression (39). 
It is crucial to recognise early clinical phenotypes for a range of traditional disorders, 
including BD, overlap. Syndromes such as mania and psychosis are typically late 
phenotypes, and need for care precedes emergence of these ‘defining’ labels.  
Therefore, to be relevant, clinical staging models must be designed within a 
transdiagnostic context, rather than traditional silos. 
Stage 0 denotes people who are asymptomatic but at increased risk, stage 1 with 
subthreshold symptom and decreased functioning, with stage 2 indicating first onset 
illness, in keeping with recognised diagnostic criteria. Stages 3 and 4 indicate 
recurrent and persistent illness, with accruing disability.  
This is intuitively appealing, enabling clinical phenomena to be linked to treatments 
as well as neurobiological biomarkers and targets of treatment response/non-
response, across diagnostic boundaries (40,41). This model is neither deterministic 
nor pessimistic and incorporates a “reverse gear”; one can move from stage 4 back 
to stage 3, if persistent and recurrent illness stabilises with optimal therapy, and 
represents an optimistic shift in thinking from earlier staging models. It also alleviates 
concerns about theories of inevitable progression and worsening facets of illness, 
such as cognitive functioning (as illustrated above). This is dependent on validity and 
reliability of “stages” and demonstrable efficacy of treatments, preventing further 
progression. Concurrent with this is evidence that suggests some interventions are 
more efficacious for people who have experienced fewer illness episodes. This 
consists of predominantly post-hoc analyses, with dichotomising data (and resultant 
caveats). Re-analysis of a group psychoeducation trial found a cut-off of 6 episodes 
affected 5 year recurrence of mood episode in euthymic BD (42) and a large, multi-
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centre RCT of cognitive behaviour therapy (CBT) found decreased recurrence in 
people experiencing 12 episodes or less (HR=0.51)(43). Similar analyses exist in 
trials of olanzapine (decreased time to remission in first episode compared to multi-
episode mania at 12 weeks (44) and lithium prophylaxis in unipolar and BD, finding 
reduced recurrence in BD of less than ten years’ duration (45). These studies are, 
however, cross sectional, and people with longer illness are more likely to have 
treatment resistance. Furthermore, recent literature from prospective follow-up of 
people with history of one manic episode, that relapse prevention (i.e., lack of 
recurrence) may be associated with less grey matter volume loss (46) and 
improvement in neuropsychological functioning (47), though teasing apart effects of 
confounders such as antipsychotics and substance misuse will require larger 
studies, and longer-term follow-up. 
Direct trial evidence for specific interventions in first episode mania 
Pharmacological 
Conus et al compared chlorpromazine and olanzapine as adjuncts to lithium in first 
episode mania in an 8 week RCT, finding similar safety but possibly earlier and 
higher remission rates with olanzapine (48). The only maintenance trial in people 
with post-first episode mania recruited 61 people with FEMP whose symptoms had 
been well controlled with quetiapine and lithium and randomised them to quetiapine 
(mean dose 437.5mg) or lithium (mean level 0.6mM). Using a mixed-model, 
repeated measures design they found lithium superior to quetiapine on clinical 
measures (Young Mania Rating Scale (YMRS), Brief Psychiatric Rating Scale 
(BPRS), clinical global impression), and functioning (49). What can be taken from 
these two pharmacological studies is that lithium does exert a beneficial effect in this 
patient group, at a relatively low dose, in keeping with the doses of antipsychotics 
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needed in first episode schizophrenia (50). It is also acknowledged that any 
intervention studies are difficult to recruit to, and possibly large drop-out rates and 
smaller number of potential participants than first episode populations in general. 
Psychological 
As pointed out by Vallarino et al, most psychotherapy studies have focused on 
samples outside the age range of first onset illness (51). Taking an evidence-
mapping approach they identified 5 studies in people with first episode BD, four of 
which were case series, one a controlled trial (52). Here we will consider only trial 
data. The first RCT, an adjunct to the pharmacotherapy trial, above, was an open 
label trial of manualised CBT versus treatment as usual (TAU), with 20 in each 
group. A significant difference was found in depression, though not manic symptoms, 
at 18-month follow-up. We identified a further pilot RCT of recovery-focused CBT 
versus TAU, which recruited 67 people (33 to CBT), with onset of BD in the last 5 
years, around 80% having BD. The authors found decreased time to relapse of any 
mood episode in the CBT group at 15 months (HR=0.37), and better self-reported 
recover (53). Although better than TAU, interpretation is difficult, given lack of an 
active control intervention (54). 
Service level interventions 
Kessing et al examined a specialist mood disorder clinic (specialist pharmacological 
and psychological treatment, including group psychoeducation) versus TAU in an 
RCT of 158 people admitted to hospital with 1st, 2nd or 3rd episode mania/BD. They 
found significant improvement in rehospitalisation after follow-up of 2.5 years.  Post-
hoc analysis identified non-statistically significant improvement for younger patients 
(aged 26 and below (55). 
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Current service level interventions for young people with first episode 
mania/bipolar disorder. 
There is substantial international variability in care for people with first episode 
mania. Several classifications exist (56), with limited focus on low and middle-income 
countries (LMIC). For this review, systems include those with a) universal health care 
(UHC) systems- including social health insurance with ‘residual’ systems, b) UHC 
systems with Specialised Streams of Care (SSC) for early psychosis or BD, c) 
managed care systems or voluntary health insurance (VHI), d) systems in LMIC 
settings and e) University or tertiary research clinical settings.  
Several European, Canadian and Oceanic health systems follow the UHC model. 
Here, those with BD and early stage BD access hospital and outpatient care through 
existing pathways for severe mental illness. Services are based on age, with 
CAMHS for those under 18 and adult services. Pertinently, this falls in the middle of 
peak age of onset (19). Additionally, limited resources and prioritisation of more 
severely unwell can lead to EI being neglected. Furthermore, those with early BD 
typically do not identify themselves as having enduring or severe mental illness. 
Therefore, poor access to, and engagement with services can occur, with 
consequent worse outcomes.  
Specialised access and care pathways can create clearer care, minimise stigma and 
improve availability and EI uptake. This is possible in the UK, Canada and Australia, 
where established Early Psychosis programmes exist. Additionally, Ireland, UK and 
Australia have youth-specific care, which may improve access (57). Complex 
managed care systems (e.g. United States) also incorporate early psychosis 
programmes (e.g. Co-ordinated Specialty Care centres) (58). In several LMICs, 
modified voluntary health insurance and ‘residual’ governmental health care provides 
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care for BD, often in later illness. Lower acceptance of mental illness as a health 
issue, higher stigma and resources pose problems, making EI less pragmatic (59). 
Several University affiliated research clinics offer early intervention for those at high-
risk of BD, and children and adults with BD (60). While these settings generate 
valuable evidence, substantial improvement in dissemination to scale within local 
health systems is required. Intervention trials across services could help develop 
evidence to inform best practice within services. Outcomes, including quality of life, 
satisfaction with care and costs will all need to be understood to inform policy 
makers and clinicians regarding future services.  
  Clinical practice guidelines and early stage BD: current status   
Clinical guidelines are relatively silent on treatment in first or early treatment seeking 
episodes of mania or BD. In our examination of guidelines published (or updated) in 
the last decade, eight guidelines refer to the first manic episode or early intervention. 
Three of these guidelines refer to indications for maintenance pharmacotherapy in 
first-episode mania; the World Federation of Societies of Biological Psychiatry 
(WFSBP) guidelines on Maintenance treatments in BD (61), the Taiwanese (62) and 
South African (63). The British Association for Psychopharmacology (BAP) 
guidelines do make comment on early intervention for BD, at individual and service 
level (64) . At an individual level BAP note lack of evidence, suggesting similar 
treatments to “mature” illness, and at service level suggest access to EI services, 
and a specifically trained psychiatrist. BD-specific guidelines recommend 
maintenance treatment for first episode mania depending on illness severity 
(WFSBP (61)), persistent disability (63), family history of BD (61, 62), suicide 
attempts and comorbid psychotic features (62).  
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The Canadian Network for Mood and Anxiety Treatments (CANMAT)/ International 
Society for Bipolar Disorders (ISBD) 2018 guidelines incorporate discussion on 
staging, first episode and recommend maintenance treatment early in illness course, 
after a first manic episode (65). Similarly, the Royal Australian and New Zealand 
College of Psychiatrists recommend consideration of maintenance treatment from 
the very first episode of mania (66). Conversely, the International College of 
Neuropsychopharmacology (CINP) guidelines suggest that those with first episode 
mania may be exempt from maintenance treatment recommendations (67).  
Another guideline referring to care for those with first episode manic psychosis in EI 
services is the Australian Clinical Guideline on Early Psychosis (ACGEP) (68). This 
specifically identifies sodium valproate as second-line mood stabiliser for acute 
treatment of a first manic psychotic episodes (It is considered first-line treatment in 
many other BD-specific guidelines (e.g., CANMAT, 2018, WFSBP). While ACGEP 
permits use of sodium valproate in women of child-bearing age (albeit with caution), 
NICE recommend against use altogether (69).  
The ACGEP contains general recommendations regarding access, risk 
management, CBT, case management and supporting vocational recovery.  This, 
the Royal Australian guideline for schizophrenia (70) and NICE guidelines on 
psychosis and schizophrenia (71) do not distinguish between recommended duration 
of maintenance medication between schizophrenia spectrum disorders and BD in 
first episode psychosis.  
Similarly, the principle of gradual medication dosing (‘start low, go-slow’) 
recommended by ACGEP may contradict loading-doses used for sodium valproate, 
where early use of higher doses is recommended (WFSBP 2009); this probably 
reflects differences in use of antipsychotic and mood stabiliser medications. 
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  There is a similar lack of clarity in the NICE Guidelines for Psychosis and 
Schizophrenia, suggesting following the NICE Bipolar guideline, which offers no 
advice on maintenance antipsychotic/mood stabiliser medication after first episode 
(NICE’s Psychosis guideline suggesting review after one to two years.)   
Recommendations and future directions 
When FEP services exist, people with first episode mania should be incorporated 
into these services, and care tailored individually. 
People presenting with first episode mania should be offered the following 
interventions.  
Pharmacological treatment for acute mania should be in keeping with 
recommendations for established illness, though once in remission thought should 
be given to making maintenance treatment as tolerable as possible, with monitoring 
of side-effects. Lithium could be considered the gold standard for maintenance 
treatment, though individually there may be concerns regarding adherence and 
tolerability. Here, low dose antipsychotics could be considered, with more tolerable 
medications with less propensity for weight gain considered. Cautious initial use of 
medications and slow titration is preferable, as early experiences of tolerability prime 
later expectations and subsequent adherence, with major long-term consequences. 
Initiating (and continuing) maintenance treatment should be based on natural course 
of illness, acknowledging people presenting to services usually have prior 
experience of depression/hypomania/mania, and also take into account variability in 
efficacy of antipsychotics as maintenance therapy in BD (72). Psychological 
interventions might be more efficacious if given early, and should emphasise on 
psychoeducation, at group or individual level.  
 18 
Other principles of early intervention should be considered; holistic case 
management, family intervention, vocational recovery, physical health interventions 
and treatment for co-morbid drug and alcohol misuse/dependence.   
Before definitive guidance can be given more research is required, to provide level 1 
evidence. 
First, determining specific interventions (pharmacological and psychological), their 
dosage, timing and effectiveness in early illness stages and phases is critical. At a 
service level, monitoring of people who have experienced first episode mania within 
FEP services will be necessary, to evaluate effectiveness against outcome 
measures such as relapse, functioning and vocational outcomes (as seen in non-
affective psychosis). Greater public and systemic education, emphasising 
importance of EI in BD and associated disorders is critical. A specific focus on 
improving access to care within locally available services is paramount, as well as 
maintaining care to prevent relapse and deterioration in functioning.   
Word count 3907 words 
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Clinical differences between first episode mania and schizophreniform 
psychosis 
 Bipolar psychosis Schizophreniform 
psychosis 
Duration of untreated 
psychosis 
Shorter (73) Longer 
Treatment response 
(pharmacological) 





















Current clinical guidelines encompassing first episode mania 
Guideline Group (Year) Guidance relating 
to first episode 
mania? 
Intervention suggested 
British Association of 
Psychopharmacology (BAP) (2016) 
Yes Monitor for risk of BD in 
those with Unipolar MDD 
Aim to prevent recurrence, 
and further disability 
Those with acute mania 
should be offered early 
intervention, including 
hospitalisation 
Assessment should be 
undertaken by a trained 
psychiatrist 
Canadian Network of Mood and 
Anxiety Treatments (CANMAT- 
International Society for Bipolar 
Disorders (ISBD) guideline (2018) 
Yes To initiate comprehensive 
treatment from the first 
episode 
Effective maintenance 
treatment should be 
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considered from an early 
stage 
International College of Neuro-
Psychopharmacology (CINP, 2017) 
Yes Those with first episode 
mania are considered 
eligible for exemption from 
the recommendation for 
lifelong prophylaxis- 
especially if the risks of 
medications on physical 
health are high 
Royal Australian and New Zealand 
College of Psychiatrists (2015) 
Yes - Maintenance treatment 
should be considered 
from the first episode of 
mania  
- People should be 
provided with support 
to come to terms with 
the illness (acceptance)  
World Federation of Societies of 
Biological Psychiatry (WSFBP)- 
Guidelines for Maintenance 
Treatment (2018) 
Yes Adopts recommendations 
from Dutch guidelines, that 
those with first episode 
mania should be considered 
for maintenance treatment 
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if they have a positive family 
history or a severe episode 
Australian Clinical Practice 
Guidelines on Early Psychosis- 2nd 
Edition (2016) 
Yes Recommendations specific 
for first episode mania with 
psychosis 
- Provides pharmacologic 
treatment algorithm for 





based on several factors. 
 
Table 3  
Summary Table 
1. First episode mania is recurrent and presents many years before 
diagnosis. 
2. Further studies are required, examining pharmacological, psychological 
and social interventions. 
3. Treatment guidelines for bipolar disorder and first episode psychosis 
should incorporate tailored care for first episode mania and suggestions 






My Experience with Bipolar Disorder 
My struggles with mental health began at age 14 when I started to experience some 
symptoms of depression; however, it was when I started to develop episodes of hypomania at 
16 when things began really getting out of hand. These episodes came as a shock to everyone 
around me as I was always known as a stable, stoic, polite young boy.  
In my first episode of hypomania, I had seemingly boundless energy levels and was 
fascinated (perhaps I should say obsessed) with business. I admired Richard Branson and 
decided that I was capable of doing well in school whilst forming a business. I led my 
school’s Young Enterprise project and was getting very good grades, but it was short-lived. I 
began to get too high and felt like I was good enough at build a huge business and wanted to 
go to China to make my business flourish. I began to skip school and didn’t do my school 
work, as I thought my business goals should take precedence and believed that I didn’t need 
to put much effort in to be able to achieve good grades at school. Alongside this, I began to 
experience insomnia, had a constant need to pace and was getting very frustrated. My 
behaviour began to alienate everyone around me.  
I felt depressed, was guilt-ridden and tried to make amends with people, feeling confused 
about what had overcame me during that period of time. This realisation, however, didn’t 
prevent future episodes. I had another episode where my new fascination was with the rapper 
Eminem. I was determined to go to Detroit and make a career for myself as a rapper. At this 
stage, my friends had had enough of my behaviour and left me completely. I felt isolated and 
began to realise that something was seriously wrong with me. I was plagued by questions 
within my head, like: ‘Am I crazy? Am I weak? Am I a bad person?’ I questioned whether I 
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should see a professional, but was worried about the stigma attached to seeking psychological 
help. I tried to muster up the courage, but my priorities changed as my sister was diagnosed 
with Leukaemia.  I tried to be there for my sister whilst doing a lot of school work to catch up 
with work I’d neglected the year before. I enjoyed spending a lot of time with my sister, 
knowing she may not have much time left. I made an effort to put on a brave face, but my 
mental health was still poor. It was, in some ways, even worse. My insomnia was still very 
bad, and I began experiencing rapid cycling symptoms. I knew people around me could see 
behind the mask, but I managed to do well in my education while seeing my sister frequently. 
It would have been what she wanted- but I burnt out.  
At the end of the year, once she was better, a severe mixed episode took over my life. I 
experienced hallucinations (visual and auditory), odd delusions including grandiose delusions 
as well as all of the symptoms I had experienced up to that date, but to a higher level. I was 
referred to see a mental health team, where I had weekly sessions. A psychiatrist sat at the 
back of the room taking notes, while a therapist and I discussed how I was feeling.  
During this episode, I was a huge threat to myself and engaged in risky behaviour as I 
thought I would be invulnerable to the repercussions. This is an example of my delusions of 
grandeur; I thought nothing anyone or anything could do would be able to break me. I am 
appalled, looking back, that I wasn’t hospitalised. These behaviours included walking at all 
hours of the night, hanging around with dangerous people and spontaneously taking a 
dangerous quantity of drugs or alcohol. During that episode, if I had been mugged, I would 
have started a fight and could have potentially been seriously hurt.  
At other times during this episode I felt completely alone, anxious and unable to move from 
my room. I felt sad and depressed and unable to do anything. Yet, I was angry, full of energy 
and felt a need to pace and be on the move. This oxymoron was beyond frustrating and made 
me feel desperate, like I had no hope.  
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The psychiatrist explained to my family that he was confused about my symptoms, saying: 
‘Sam paints a very complex picture.’ They prescribed Phenergan to help me with my sleep 
and I took this at 100mg. It seemed to help with the sleep, but the rest of my symptoms 
persisted. As several weeks had passed without any progress on diagnosis, my mum asked 
whether I could possibly have bipolar disorder, since she had observed periods of extreme 
high and low moods. They disregarded this idea as they felt that the current episode couldn’t 
be explained by bipolar disorder. They failed to enquire further on episodes in the past and 
failed to ask my family whether any of my relatives had bipolar disorder. I have two relatives 
who have suffered from bipolar disorder. After approximately 12 weeks of work together, 
they explained that I might have borderline personality disorder, but that they were still 
uncertain. They said they would refer me to the “MAP” team (for Mood, Anxiety and 
Personality disorders).  
At the time, I felt positive about the experience with my initial team. I believed the 
psychiatrist’s opinion that I painted a complex picture and accepted the suggestion of looking 
into borderline personality disorder. I felt unaware of what was happening to me, so even 
though I didn't see many parallels, I accepted that they must be right. However, when I 
mentioned the illness to my girlfriend at the time, she said that she didn't believe I could have 
this disorder and said that I didn't seem insecure in our relationship at all. She felt like my 
issues didn't have anything to do with interpersonal relationships.  
It took a long time for me to be transferred to the MAP team. They explained the transition 
time was due to difficulty in transferring a patient from adolescent to adult mental health 
services. I felt abandoned and hopeless, but was glad that the major episode had ended. Once 
I was under their care, I saw a social worker there every few weeks. She treated me in quite a 
patronising manner. She said: 'I think you'll be happy that they are thinking of changing the 
name from borderline personality disorder to emotionally unstable personality disorder.' This 
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frustrated me a lot and I felt like my issues were not being taken seriously at all. For this 
reason, I started to question whether I was making out I was more ill than I was. I questioned 
whether they were correct and wondered if I had something wrong with my personality. This 
knocked my self-esteem and made me believe in myself less than I ever had before.  
From the time that I left my first team, it took approximately 8 months to be seen by a 
psychiatrist at the MAP team. I was adamant to take medication, but she refused my request 
for a long while. After some time, she prescribed 500mg of Sodium Valproate. I began to feel 
a little hyper at this low dose, but nowhere near as manic as I had been in previous episodes. I 
wasn't aware that this was a low dose as I trusted the psychiatrist's opinion. I wondered why I 
am still ill and this made me question further whether it was a personality issue that couldn't 
be solved by medication.  
At this time, I took part in a research project at Kings College. The doctor in charge of the 
project took me under his wing. We had chats and within a few times of meeting with him, he 
realised that a lot of my symptoms and my history were compatible with a diagnosis of 
bipolar disorder. He was kind enough to send a letter to the MAP team, describing my history 
and saying that they should reassess whether I fit a diagnosis of bipolar disorder. I researched 
into bipolar disorder extensively and when I asked people if this fit me, people said that this 
diagnosis made more sense. The diagnosis made me feel a lot more comfortable and made 
me feel understood. This reduced the amount of time I spend questioning whether I was a bad 
person. I could accept myself more. I participated in other research projects within Kings 
College. All of the researchers were fantastic and they all treated me with respect. I felt 
understood and felt like there was no judgement from them.   
The MAP team gave me a new diagnosis of bipolar disorder and incrementally brought me 
up to a high dose of 2g of sodium valproate. On this very high dose, I was very lethargic and 
down, but I felt relieved that I wasn’t suffering from mania anymore. I was happy that my 
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highs weren't hurting me or those around me. I would meet with the psychiatrist once a 
month and we decided to keep me on the same medication. After a while I became quite 
frustrated on this dose, yet my psychiatrist tried to convince me to stay on it. I felt depressed 
and my voice wasn’t being heard, so I began to slowly taper off from the sodium valproate. I 
then experienced another severe mixed episode. I was seen by a crisis team and they gave me 
someone to speak to at the time. I was happy that I was given someone to talk to twice a 
week and this made me feel that someone cared which helped considerably. When I say the 
experience was very positive, I mean that one of the workers there helped me a lot. He was 
only available within the sessions though and when I would ring up asking to see anyone, 
they would be cold and tell me I should just go to A&E.   
During this episode, I felt suicidal and I made a number of suicide plans. I was very frustrated 
and was very worried that I would severely hurt someone and so I was adamant to be 
hospitalised. I needed to pace at all times and my frustration was severe. I was brought up in 
a way that developed a lot of self-control within me and I tried my very hardest to keep it all 
in. I went to the hospital on several occasions (St Georges and Kings College), but they 
refused me. This deeply saddened me, but I managed with time to get out of this episode. 
This made me feel like I wasn't being heard and I felt like people weren't taking my mental 
health seriously enough.  
The MAP team then started me on a small dose of 50mg of Quetiapine. I experienced another 
hypomanic episode. They upped my Quetiapine to 100mg and then to 150mg as my doctor 
saw that I needed more sedation. I was involved in sales and was working 70 to 80-hour 
weeks. My frustration levels were high and I barely slept at night. When I made it out of the 
episode, I got very depressed and felt more guilt than I ever had done before.  
My mum, who was very worried at the time, contacted the research psychiatrist and told him 
what had transpired. He was quite shocked at the prescription of 150mg of Quetiapine as this 
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dose is too low to properly prevent manic episodes. At my mother’s request he referred me to 
another psychiatrist, another researcher at Kings College, who accepted me as a private 
patient. My experience with him has been fantastic. I am now on 300mg Quetiapine and 
200mg Lamotrigine and I have since been symptom free for the past 18 months.   
My levels of guilt have improved due to feeling more accepted and realising that this issue is 
not part of my personality; it is a physical issue which needed to be solved through 
medication. Both Sameer and Paul have helped me accept that I have bipolar disorder, that it 
can be managed and that I can lead a productive, meaningful life. Family therapy helped my 
family to understand my illness and accept it.  
My concentration and cognitive abilities began to improve once I was stable for longer than a 
few months, but I still had work to do to get back to where I was before. I realised this when I 
initially began cognitive remediation therapy (CRT) and found a lot of the cognitive tasks 
difficult. During the sessions I worked hard, slowly developing my metacognitive skills. I 
then began reading and doing psychological research on my own. Now I am able to do well 
in my degree. I’m still not at my peak, but eager to carry on trying hard. I am able to get on 
with tasks, but more importantly I am consistent and able to focus on one thing without 
switching goals frequently. I am passionate about my psychology course and am very happy 
and content overall.  
 
 
